Hye Yeon Chon

Clinical associate professor

Yonsei University College of Medicine

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Cancer Biology Cancer Biology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hye Yeon Chon is a Clinical Associate Professor at Yonsei University College of Medicine in South Korea. Her research focuses on hepatocellular carcinoma, liver diseases, and the gut microbiome, as evidenced by her recent publications on metastatic small cell neuroendocrine carcinoma, hepatitis B virus-related liver conditions, and novel predictive models for cancer risk. She is actively engaged in advancing therapeutic approaches for chronic hepatitis B and enhancing predictive accuracy for liver cancer prognosis.

Articles (11)

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (3)

Sang Hyuk LEE

SOUTH KOREA

View details

Seung Yun Han

SOUTH KOREA

View details

Dae Sung Kim

Assistant professor

Konyang University Hospital

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hye Yeon Chon

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Metastatic Small Cell Neuroendocrine Carcinoma Presenting with Liver Metastasis

Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma

CAGE‐B and SAGE‐B models better predict the hepatitis B virus‐related hepatocellular carcinoma after 5‐year entecavir treatment than PAGE‐B

Bile Acids: Major Regulator of the Gut Microbiome

Liver Cirrhosis and Sarcopenia

Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B

Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients

Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B

Addition of liver stiffness enhances the predictive accuracy of the PAGE‐B model for hepatitis B‐related hepatocellular carcinoma

Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B

Advanced liver fibrosis predicts poor cardiovascular outcomes in patients with type 2 diabetes

Collaborators (3)

Sang Hyuk LEE

Seung Yun Han

Dae Sung Kim

Make your next move.